Ipamorelin
A selective synthetic pentapeptide agonist at the ghrelin receptor (GHS-R1a), developed at Novo Nordisk to stimulate GH release with minimal co-stimulation of cortisol and prolactin relative to earlier GHRPs. Reportedly investigated for GH stimulation, body composition, and recovery. Pharmacological characterisation is thorough; no large-scale controlled trials establishing therapeutic efficacy in healthy adults have been published, and no approved pharmaceutical product exists.
Side effects & risks
Ipamorelin has not been approved for human therapeutic use by any major regulatory authority, and no large-scale, long-term safety studies in humans have been published. The risk profile for unsupervised use is, in practical terms, unknown.
As a growth hormone secretagogue, ipamorelin stimulates the pituitary to release growth hormone. The long-term consequences of chronic, repeated GH stimulation from an exogenous secretagogue — including any effects on pituitary function, IGF-1 levels, and downstream metabolic parameters — have not been evaluated in human safety trials of the durations relevant to community usage patterns.
The published human pharmacology studies assessed ipamorelin over short periods (single dose or several-day dosing). Raun et al. (1998, European Journal of Endocrinology, vol. 139; PMID 9849822) conducted the foundational characterisation work in conscious swine and in vitro pituitary cell cultures. In the limited human endocrinology studies, GH pulses were induced without significant observed changes in cortisol, prolactin, or ACTH — a property that has been cited as a potential selectivity advantage over earlier secretagogues, though the human safety dataset remains too small to draw firm conclusions.
Community reports of adverse effects include water retention, mild bloating, headache, and transient lethargy. These are reported without controlled-trial context and causality cannot be established. Potential drug interactions, particularly with agents affecting the GH/IGF-1 axis, have not been systematically studied.
Ipamorelin is not approved for human therapeutic use in any major regulatory jurisdiction. Individuals obtaining it as a research chemical assume an undetermined risk profile.
Evidence summary
Latest studies
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
Researchers systematically searched the published literature on six peptides marketed for injury recovery and athletic performance - BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu - and found that about two-thirds of the studies were preclinical, mostly in rats. The handful of human studies were small, often lacked robust control groups, and showed at best modest changes in metabolic bone health measures and degenerative knee pain. The authors also flag documented risks, including congestive heart failure with MK-677 and insulin resistance, and conclude the marketing claims are not yet substantiated by human trials.
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
This review discussed the growing use of peptides and peptide-like drugs to enhance muscle, fat loss and recovery in sport and bodybuilding. It is an expert commentary summarising the field, not a new experiment. The authors explained that these peptides, including growth-hormone-releasing peptides such as ipamorelin, growth-hormone-releasing hormone analogues such as CJC-1295 and sermorelin, and fragments such as Frag 176-191 and KPV, are promoted as more selective and supposedly safer than anabolic steroids. However, they stressed that the clinical evidence is limited, because most studies tested careful medical doses, not the very high or combined doses often used in bodybuilding. They pointed to emerging risks including strain on the heart, insulin resistance, abnormal blood fats, and mood and psychiatric instability, and warned that a largely unregulated supply means products are often mislabelled or contaminated. They also noted that how widely these peptides are used, especially among ordinary gym-goers and younger people, is simply unknown. The authors concluded that peptides remain experimental substances with poorly understood long-term risks, and that until long-term studies exist, their use in competitive and recreational settings should be regarded as high-risk and ethically problematic.
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
This review pulled together human and lab-based research from 2020 to 2025 on injectable peptides marketed for muscle, joint and tissue recovery in sports medicine. It is a structured summary of existing studies, not new research, and the authors rated the underlying evidence as generally weak. They sorted the peptides into five groups. Only GLP-1 receptor agonists such as semaglutide had repeatable randomised-trial evidence of easing symptoms, specifically in knee osteoarthritis, and that benefit seemed to come mainly from weight loss and possible anti-inflammation rather than from rebuilding cartilage, which was not shown. Collagen-based injections showed early, limited signs of helping recovery after surgery in small single-centre studies. The so-called regenerative peptides (such as BPC-157 and thymosin derivatives) and growth-hormone-boosting peptides (such as CJC-1295, ipamorelin and tesamorelin) were described as still experimental, with unclear safety, concerns about product quality and contamination, and widespread bans in competitive sport. The authors concluded that most injectable peptides for sports use remain experimental, that use should be limited to approved medicines for approved conditions or to proper research, and that athletes should be counselled about uncertain benefit, quality and anti-doping risks.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“GHRP-2, GHRP-6, hexarelin, ipamorelin: what 'growth hormone secretagogue' actually covers”
An educational thread clarifying what the term growth hormone secretagogue covers, comparing GHRP-2, GHRP-6, hexarelin, and ipamorelin and how they differ within that class.
“CJC-1295 + Ipamorelin”
A discussion of the widely used CJC-1295 plus Ipamorelin combination, the classic GHRH-analog-plus-GHRP pairing, likely covering reported dosing schedules and expected effects.
“CJC-1295 + Ipamorelin for bulking or cutting?”
A user asks whether the CJC-1295 plus Ipamorelin stack is better suited to a bulking or a cutting phase, inviting community input on how GH-secretagogue effects fit different body-composition goals.
“"CJC-1295 + Ipa no DAC" VS "Tesamorelin + Ipa"”
A comparison thread weighing CJC-1295 (no DAC) plus Ipamorelin against Tesamorelin plus Ipamorelin, asking which GHRH-analog pairing the community regards as more effective for their goals.
“CJC-1295 + Ipamorelin”
A thread on the CJC-1295 plus Ipamorelin combination, likely seeking or sharing reported protocols for the popular GH-secretagogue stack.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| GH secretagogue (community-reported) | SC injection | 100–300 mcg | 2–3× daily (including pre-sleep) | 8–12 weeks |
| Combination with CJC-1295 (community-reported) | SC injection | 100–200 mcg ipamorelin | 2× daily | 8–12 weeks |
Frequently asked questions
- What are the known risks of ipamorelin?
- No large-scale, long-term human safety studies have been published. Short-term pharmacology studies demonstrated GH secretion without significant cortisol or prolactin elevation, but these studies do not establish a long-term safety profile. Key unknowns include the effects of chronic pituitary stimulation on pituitary function and IGF-1 levels over extended use. Community reports describe water retention, bloating, headache, and lethargy. The risk profile for sustained use is, in practical terms, unknown.
- What makes ipamorelin different from other GHRPs like GHRP-6?
- Ipamorelin was developed with a more selective receptor binding profile than GHRP-6 and hexarelin. In animal studies and limited human pharmacology, ipamorelin produced GH secretion without the significant cortisol, prolactin, or ACTH stimulation seen with earlier GHRPs at comparable doses (Raun et al., 1998). This selectivity profile is the primary distinguishing feature in the published literature, though the long-term clinical significance of this distinction in humans has not been established.
- Is ipamorelin often used with CJC-1295?
- Community reports frequently describe use of ipamorelin combined with CJC-1295. The rationale reported is that the two peptides act via different but complementary pathways — ipamorelin via the ghrelin receptor and CJC-1295 via the GHRH receptor — with a hypothesised synergistic effect on GH release. This combination has not been studied in controlled human trials; the evidence base is mechanistic inference and community self-experimentation.
- How strong is the evidence for ipamorelin?
- Ipamorelin has a well-characterised pharmacological profile from its Novo Nordisk research origins. The pharmacology studies in animals and short-term human endocrinology work confirm its mechanism of action and GH-secreting activity. However, no large controlled human clinical trials for body composition or clinical outcome endpoints have been published. The evidence grade for performance or body composition claims is insufficient.
- Is ipamorelin legal to buy or use?
- Ipamorelin is not approved for human therapeutic use in the United States, Australia, Canada, the UK, or most of the EU. In most jurisdictions it is sold as a research chemical. Regulatory status varies by country and is subject to change; verify current status with a qualified legal or clinical professional.